Humanigen will get an upfront payment of $6m upon execution of the licensing agreement. Credit: Paweł Czerwiński on Unslpash.

Humanigen has executed a licensing agreement with Telcon RF Pharmaceutical and KPM Tech for development and commercialisation rights of its Covid-19 drug lenzilumab for South Korea and the Philippines.

This deal, worth $20m, marks Humanigen’s first licensing transaction in the Asia-Pacific region.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Upon execution of the licensing agreement, Humanigen will receive an upfront payment of $6m and $14m in two payments for achieving specified milestones in the US.

Telcon and KPM Tech will be in charge of obtaining regulatory approval and subsequent commercialisation of lenzilumab in its territories.

Furthermore, Humanigen will get double-digit royalties on receipt of those approvals on net sales subsequent to commercialisation.

Telcon, an affiliate of KPM Tech, produces liquid formulations, tablets, pills, capsules, other pharmaceutical products and communication equipment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Humanigen Asia-Pacific Region head Bob Atwill said: “Telcon and KPM Tech invested in Humanigen with a view to increase involvement moving forward.

“Humanigen’s expansion strategy in the Asia-Pacific region is well underway and this is the first of other anticipated licensing transactions for lenzilumab in Covid-19 hospitalised patients.”

Estimates show that the number of Covid-19 cases in South Korea and the Philippines is over 412,000.

Telcon and KPM Tech CEO Ji-Hoon Kim said: “Lenzilumab has a significant part to play in the treatment of patients in the pandemic and beyond. We are honoured to be selected to develop and potentially launch lenzilumab in South Korea and the Philippines.”